History of another primary malignancy except for \r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence \r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease \r\n* Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ)
Patients diagnosed or treated for malignancy other than MCL are not eligible unless they meet one of the following exceptions:\r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before registration and felt to be at low risk for recurrence by the treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
History of other malignancy within the past  years prior to first dose of AMG  except: Malignancy (other than in situ) treated with curative intent and with no known active disease present for .  years before first dose of AMG  and felt to be at low risk for recurrence by the treating physician. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. Adequately treated in situ cancer without evidence of disease. Prostatic intraepithelial neoplasia without evidence of prostate cancer Adequately treated urothelial papillary noninvasive carcinoma
History of other malignancies, except: \r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
Adequately treated non-melanoma skin cancer or lentigo maligna
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of ipilimumab (IP) and of low potential risk for recurrence.\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease.
History prior malignancy except:\r\n* Malignancy treated with curative intent and no known active disease present for ?  years prior to initiation of therapy on current study;\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna (melanoma in situ) without evidence of disease;\r\n* Adequately treated in situ carcinomas (e.g., cervical, esophageal, etc.) without evidence of disease;\r\n* Asymptomatic prostate cancer managed with watch and wait strategy;\r\n* Myelodysplastic syndrome which is clinically well controlled and no evidence of the cytogenetic abnormalities characteristic of myelodysplasia on the bone marrow at screening
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
History of prior malignancy, with the exception of adequately treated non-melanoma skin cancer, malignancies treated with curative intent and with no evidence of active disease for more than  years, or adequately treated cervical carcinoma in situ without current evidence of disease
History of other malignancy within the past  years prior to enrollment except: Malignancy (other than in situ) treated with curative intent and with no known active disease present for ?  years before enrollment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; Adequately treated in situ cancer without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer; Adequately treated urothelial papillary noninvasive carcinoma.
History of prior malignancy, with the exception of the following: malignancy treated with curative intent and with no evidence of active disease present for more than  years prior to screening and felt to be at low risk for recurrence by treating physician; or adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled non-melanomatous skin cancer; or adequately treated cervical carcinoma in situ without current evidence of disease.
History of another primary malignancy within the past  years except for:\r\n* Basal cell skin cancer\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ)
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Non-metastatic prostate adenocarcinoma, or treated superficial non-invasive bladder cancer\r\n* Adequately treated carcinoma in situ without evidence of disease (eg, cervical cancer in situ)
History of another primary malignancy except for: ) Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence. ) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. ) Adequately treated carcinoma in situ without evidence of disease (e.g., superficial bladder cancer).
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study treatment and low potential for risk of recurrence\r\n* Adequately treated non-melanoma skin cancer of lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
History of another primary malignancy except for: A) malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence; B) adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; C) adequately treated carcinoma in situ without evidence of disease, e.g. cervical cancer in situ; D) synchronous endometrial and ovarian cancer is allowed, provided the endometrial cancer is presumed stage IA/B grade /
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease\r\n* >=  years before the first dose of study drug and of low potential risk for recurrence\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ
History of another primary malignancy except for: (i) OPSCC with loco-regional recurrence after  months of curative-intent treatment and amenable to salvage surgery; (ii) malignancy treated with curative intent and with no evidence of active disease >=  years before the first dose of study drug and of low potential risk for recurrence; (iii) non-melanoma, skin cancer or lentigo maligna; in situ cervical, breast, prostate or bladder carcinoma
History of another primary malignancy except for: \r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ
History of other malignancy within the past  years with the following exceptions:\r\n*  Malignancy treated with curative intent and with no known active disease present and has not received chemotherapy for > years before randomization and felt to be at low risk for recurrence by the treating physician\r\n*  Adequately treated non-melanoma skin cancer without evidence of disease at the time of randomization\r\n* Adequately treated cervical carcinoma in situ without evidence of disease at the time of randomization\r\n* Adequately treated breast ductal carcinoma in situ without evidence of disease at the time of randomization\r\n* Prostatic intraepithelial neoplasia without evidence of prostate cancer at the time of randomization\r\n* Adequately treated superficial or in situ carcinoma of the bladder without evidence of disease at the time of randomization
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
History of another primary malignancy except for: malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; or adequately treated carcinoma in situ without evidence of disease, e.g., cervical cancer in situ.
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ
History prior malignancy except:\r\n* Malignancy treated with curative intent and no known active disease present for >=  years prior to initiation of therapy on current study\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna (melanoma in situ) without evidence of disease\r\n* Adequately treated in situ carcinomas (e.g., cervical, esophageal, etc.) without evidence of disease\r\n* Asymptomatic prostate cancer managed with watch and wait strategy\r\n* Myelodysplastic syndrome which is clinically well controlled and no evidence of the cytogenetic abnormalities characteristic of myelodysplasia on the bone marrow at screening
History of another primary malignancy except for: \r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence \r\n* Adequately treated non-melanoma skin cancer or lentigo maligns without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease eg, cervical cancer in situ
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease (e.g. basal cell or squamous cell carcinoma of the skin)\r\n* Adequately treated carcinoma in situ without evidence of disease (e.g., breast and cervical cancer in situ)
History of other malignancies, except: \r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease\r\n* Adequately treated carcinoma in situ or T urothelial cancer without evidence of disease
Patients diagnosed or treated for malignancy other than HCC are not eligible unless they meet one of the following exceptions:\r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before registration and felt to be at low risk for recurrence by the treating physician.\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
Patients with a history of active malignancy within  years prior to registration; note: exceptions to this requirement include adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ without evidence of disease or prostate cancers with a Gleason score <  and with prostatectomy and no lymph node involvement
Diagnosed or treated for malignancy other than MCL, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before randomization\r\n* Adequately treated non-melanoma skin cancer or melanoma in situ without evidence of disease\r\n* Adequately treated cervical carcinoma in situ without evidence of disease\r\n* Asymptomatic prostate cancer managed with active surveillance
History of another primary malignancy except for: malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; or adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ)
 History of malignancy other than B-NHL within the past  years with the exception of: Malignancy treated with curative intent and with no known active disease present for ?  years before enrollment and felt to be at low risk for recurrence by the treating physician. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. Adequately treated cervical carcinoma in situ without evidence of disease. Adequately treated breast ductal carcinoma in situ without evidence of disease. Prostatic intraepithelial neoplasia without evidence of prostate cancer. Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ.
History of another malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ
History prior malignancy except:\r\n* Malignancy treated with curative intent and no known active disease present for >=  years prior to initiation of therapy on current study\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna (melanoma in situ) without evidence of disease\r\n* Adequately treated in situ carcinomas (e.g., cervical, esophageal, etc.) without evidence of disease\r\n* Asymptomatic prostate cancer managed with watch and wait strategy\r\n* Myelodysplastic syndrome which is clinically well controlled and no evidence of the cytogenetic abnormalities characteristic of myelodysplasia on the bone marrow at screening
History of another primary malignancy except for: malignancy treated with curative intent and with no known active disease >=  years before the first dose of IP and of low potential risk for recurrence, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, or adequately treated carcinoma in situ without evidence of disease.
Diagnosed or treated for malignancy other than ALL, except: ) Malignancy treated with curative intent and with no known active disease present for >=  years before treatment; ) Adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ (e.g. cervical, breast) without evidence of disease; ) or malignancy that in the opinion of the investigator, with concurrence with the MD Anderson Cancer Center (MDACC) investigational new drug (IND) office, is considered cured with minimal risk of recurrence within  years
History of another primary malignancy except for: \r\n* Malignancy treated with curative intent and with no known active disease >= years before the first dose of study drug and of low potential risk for recurrence;\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; or \r\n* Adequately treated carcinoma in situ without evidence of disease, e.g. cervical cancer in situ
Presence of a malignant disease within the last  months, with the exception of adequately treated in-situ carcinomas, basal or squamous cell carcinoma, non-melanomatous skin cancer, or malignancies treated with curative intent and no evidence of active disease in prior  months and felt to be low risk for recurrence.
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ
History of prior malignancy except: a) Malignancy treated with curative intent and no known active disease present for ? years prior to initiation of current study; b) adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; c) adequately treated in situ carcinomas (e.g., cervical, esophageal, breast, etc.) without evidence of disease; d) asymptomatic prostate cancer managed with \watch and wait\ strategy; e) myelodysplastic syndrome which is clinically well controlled and no evidence of the cytogenetic abnormalities characteristic of myelodysplasia on the bone marrow at screening
Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease
Diagnosed or treated for malignancy other than multiple myeloma, except: a) Malignancy treated with curative intent and with no known active disease present for more than equal to (>= ) years before randomization; b) Adequately treated non-melanoma skin cancer, lentigo maligna or in situ malignancies (including but not limited to, cervical, breast) with no evidence of disease
Prior malignancy, except for adequately treated lentigo maligna melanoma, non-melanomatous skin cancer, in situ cervical carcinoma or other malignancy treated with no evidence of active disease >  years before Screening and at low risk for recurrence.
Prior malignancy, except for adequately treated lentigo maligna melanoma, non-melanomatous skin cancer, in situ cervical carcinoma, or other malignancy treated with no evidence of active disease >  years before Screening and at low risk for recurrence.
Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease
No prior malignancy with the exceptions listed below:\r\n* Malignancy treated with curative intent and with no evidence of active disease for more than  years prior to screening and felt to be at low risk (< %) for recurrence by the treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease
History of prior malignancy, with the exception of the following:\r\n* Malignancy treated with curative intent and with no evidence of active disease present for more than  years prior to screening and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease
Any prior history of other malignancy besides follicular lymphoma, unless the patient has been free of disease for >=  years and felt to be at low risk for recurrence by the treating physician, except:\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
History of other malignancies, except: \r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
History of other malignancies, except: malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study drug and felt to be at low risk for recurrence by treating physician, () adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, () adequately treated carcinoma in situ without evidence of disease, or () Gleason  prostate cancer under observation
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease (eg, cervical cancer in situ)\r\n* Adequately treated stage  breast or stage  low grade endometrial cancer
No active, second potentially life-threatening cancer; no history of another primary malignancy except for; malignancy treated with curative intent and no known active disease >=  years before the first dose of investigation product (IP) and of low potential risk for recurrence; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately treated carcinoma in situ without evidence of disease
Any prior history of other malignancy besides FL or marginal zone lymphoma, unless the patient has been free of disease for >=  years and felt to be at low risk for recurrence by the treating physician, except:\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
Subjects with a history of malignancy are not eligible with the exception of the following:\r\n* Malignancy treated within curative intent and with no evidence of active disease present for more than  years prior to screening and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease
History of prior malignancy, with the exception of the following:\r\n* Malignancy treated with curative intent and with no evidence of active disease present for more than  years prior to screening, and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease
Diagnosed or treated for malignancy other than DLBCL, except: malignancy treated with curative intent and with no known active disease present for >= years before random assignment; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately treated carcinoma in situ without evidence of disease
History of prior malignancy, except: malignancy treated with curative intent and with no known active disease present for >= years before randomization; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately treated cervical carcinoma in situ without evidence of disease
Diagnosed or treated for malignancy other than the indication under study except for\r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study treatment\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
History of other malignancy, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >=  years prior to randomization and felt to be at low risk for recurrence by the treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ)\r\n* Adequately treated stage  breast cancer
Diagnosed or treated for malignancy other than NHL for which patient will be treated, except: malignancy treated with curative intent and with no known active disease present for >=  years before subject registration; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately treated carcinoma in situ without evidence of disease
Any prior or synchronous malignancy (other than breast cancer), except i) Malignancy treated with curative intent and with no evidence of disease for ?  years prior to enrollment and considered to be at low risk for recurrence by the treating physician ii) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
History of prior malignancy, with the exception of the following:\r\n* Malignancy treated with curative intent and with no evidence of active disease present for more than  years prior to screening and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease
History of prior malignancy, with the exception of the following:\r\n* Malignancy treated with curative intent and with no evidence of active disease present for more than  years prior to screening and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease\r\n* Skin-limited Kaposi sarcoma that has not required systemic treatment within  months prior to study enrollment
History of prior malignancy, with the exception of the following:\r\n* Malignancy treated with curative intent and with no evidence of active disease present for more than  years prior to screening and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease
History of other malignancy, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >=  years prior to registration and felt to be at low risk for recurrence by the treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
History of another primary malignancy except for:\r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and of low potential risk for recurrence\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ)
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease\r\n* Low-risk prostate cancer after curative surgery
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease\r\n* Low-risk prostate cancer on active surveillance
History of another primary malignancy except for: \r\n* Malignancy treated with curative intent and with no known active disease >=  years before the first dose of study drug and or low potential risk for recurrence \r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease \r\n* Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ
EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): History of other malignancies, except: \r\n* Malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n Adequately treated carcinoma in situ without evidence of disease
History of other malignancies, except: malignancy treated with curative intent and with no known active disease present for >=  years before the first dose of study drug and felt to be at low risk for recurrence by treating physician, () adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, () adequately treated carcinoma in situ without evidence of disease, or () Gleason  prostate cancer under observation
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease\r\n* Low-risk prostate cancer on active surveillance
History of prior malignancy, with the exception of adequately treated non-melanoma skin cancer, malignancies treated with curative intent and with no evidence of active disease for more than  years, or adequately treated cervical carcinoma in situ without current evidence of disease